Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Co-ArgI-PEG modified human arginase I · 1 trial · 2 indications
The dose level at which no more than 1/6 patients experiences dose-limiting toxicity
| Arm | Type | Description |
|---|---|---|
| AEB1102 (Co-ArgI-PEG) administered via IV weekly. | EXPERIMENTAL | Co-ArgI-PEG modified human arginase I |
| Name | Type | Description |
|---|---|---|
| Co-ArgI-PEG modified human arginase I | DRUG | - |
Inclusion Criteria: * Willing and able to provide informed consent * Age 18 and older * Diagnosis of AML or MDS according to the WHO criteria * AML relapsed or refractory to at least one attempt at induction or subjects not candidates for aggressive induction regimens * MDS refractory to treatment ...
Co-ArgI-PEG modified human arginase I is an investigational small molecule being developed for the treatment of Acute Myeloid Leukemia (AML). It is currently in Phase 2 clinical development and has been studied in patients with AML or Myelodysplastic Syndrome.
Co-ArgI-PEG modified human arginase I is being developed by Spyre Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol SYRE.
Co-ArgI-PEG modified human arginase I is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
Co-ArgI-PEG modified human arginase I has been studied in a completed Phase 2 trial with the identifier NCT02732184. This trial was a multiple dose, dose escalation study in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome, enrolling 29 participants in the United States and Canada.
Yes, Co-ArgI-PEG modified human arginase I is also known as AEB1102. The clinical trial NCT02732184, which evaluated this drug, was titled 'A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS'.